Project Aura: Co-design

2019-10-08 08:47:35 | BioPortfolio


Co-design of a home-based haemoglobin monitoring system with participants with anaemia of chronic kidney disease.

Study Design


Anemia of Chronic Kidney Disease


Blood measurement


Hull University Teaching Hospitals NHS Trust
United Kingdom


Not yet recruiting


Entia Ltd

Results (where available)

View Results


Published on BioPortfolio: 2019-10-08T08:47:35-0400

Clinical Trials [5594 Associated Clinical Trials listed on BioPortfolio]

FG-4592 (ASP1517) in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis

This study is conducted to treat anemia in patients with chronic kidney disease. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin is important for the transport of o...

Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

This study examines patients with chronic kidney disease-related anemia and measures changes in the metabolism of the heart using FDG/PET scanning, before and 6 months after their health-c...

A Safety Study of Pentoxifylline for the Treatment of Anemia

Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease. Pentoxifylline is known to...

Survey on Anemia Therapy in Patients With Chronic Kidney Disease Not on Dialysis

This study is a prospective, non-interventional, cross-sectional multicenter survey. The aim is to better understand the current therapy pattern for anemia in chronic kidney disease (CKD) ...

Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anticalins® are engineered human proteins that are able to bind specific target molecules. The Anticalin PRS-080#022-DP to be investigated in this study is directed against hepcidin and i...

PubMed Articles [29361 Associated PubMed Articles listed on BioPortfolio]

Red Blood Cell Lifespan Shortening in Patients with Early-Stage Chronic Kidney Disease.

Although reduced red blood cell (RBC) lifespan has been reported to be a contributory factor to anemia in patients with end-stage chronic kidney disease (CKD), there are limited data regarding RBC lif...

Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study.

Desidustat (ZYAN1) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stimulates erythropoiesis. Stabilizing HIF via PHI is developing as a new therapeutic approach to tre...

Anemia management in cancer patients with chronic kidney disease.

Cancer and kidney disease are linked by causality and comorbidities. Observational data show an increased risk of malignancy as renal function declines. Erythropoietin stimulating agents (ESAs), which...

Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.

Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In phase 2 studies involving patients with ...

Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study.

Routine clinical evidence is limited on clinical outcomes associated with anemia in patients with severe chronic kidney disease (CKD).

Medical and Biotech [MESH] Definitions

Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)

The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.

Viral disease of horses caused by the equine infectious anemia virus (EIAV; INFECTIOUS ANEMIA VIRUS, EQUINE). It is characterized by intermittent fever, weakness, and anemia. Chronic infection consists of acute episodes with remissions.

A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal failure, either acute (KIDNEY FAILURE, ACUTE) or chronic (KIDNEY FAILURE, CHRONIC), requires HEMODIALYSIS.

A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.

More From BioPortfolio on "Project Aura: Co-design"

Quick Search

Relevant Topic

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Searches Linking to this Trial